Written by The global Technetium-99m Market was valued at USD 6.8 billion in 2025 and is projected to reach USD 10.9 billion by 2036, expanding at a CAGR of 4.7% from 2026 to 2036. The market is expected to maintain steady growth as hospitals and diagnostic centers increasingly rely on nuclear medicine for the detection and monitoring of cardiovascular diseases, cancer, neurological disorders, and bone-related conditions. Technetium-99m remains one of the most widely used medical radioisotopes because its short radioactive half-life and favorable imaging properties support high-quality diagnostic scans while limiting radiation exposure. Growing adoption of SPECT and SPECT/CT systems is further strengthening demand, while improvements in radiopharmaceutical production and healthcare infrastructure are creating additional opportunities for market participants.
👉 Get sample market research report copy now@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=77100
Market Size and Growth
The Technetium-99m market is benefiting from the expanding global need for early, accurate, and minimally invasive diagnosis. The market reached USD 6.8 billion in 2025 and is expected to increase to USD 10.9 billion by 2036, representing a 4.7% CAGR during the forecast period. Rising healthcare expenditure, population aging, and the growing incidence of chronic diseases are supporting procedure volumes. Technetium-99m is particularly important in cardiac imaging, oncology, bone scans, renal imaging, and neurological assessments, making demand relatively diversified across clinical applications. At the same time, investments in nuclear medicine facilities and improvements in SPECT-based imaging are helping healthcare providers expand their diagnostic capabilities.
Market Segmentation
By clinical service, Cardiac Scan represented the leading segment, accounting for approximately 41.2% of the market in 2025. Strong demand for myocardial perfusion imaging and the global burden of coronary artery disease continue to support the segment. Beyond cardiology, Technetium-99m is widely used for bone imaging, oncology, renal studies, and neurological applications. SPECT and SPECT/CT remain important technology platforms because they allow clinicians to evaluate physiological activity alongside anatomical information, improving diagnostic confidence in several clinical settings. From a market-development perspective, expansion of oncology and cardiovascular diagnostic services in emerging economies could broaden the addressable opportunity for Tc-99m-based procedures.
Regional Analysis
North America dominated the global market in 2025, accounting for 37.7% of revenue. The region benefits from extensive nuclear medicine infrastructure, high diagnostic imaging utilization, established radiopharmaceutical distribution networks, and comparatively strong healthcare spending. The United States remains a major contributor because of its large patient population, aging demographics, established reimbursement mechanisms, and widespread use of SPECT and SPECT/CT systems. Europe also represents a significant market, supported by mature nuclear medicine services and continuing investments in healthcare technology. Meanwhile, Asia Pacific is emerging as an attractive growth market as countries expand hospital infrastructure, install nuclear imaging systems, strengthen radiopharmacy capabilities, and improve access to advanced diagnostics. Latin America and parts of the Middle East and Africa also offer longer-term opportunities as healthcare investment and nuclear medicine capacity increase.
Competitive Landscape
The Technetium-99m market is moderately consolidated, with major companies participating across areas such as radioisotope production, radiopharmaceutical manufacturing, generator supply, distribution, and diagnostic services. Key companies include Lantheus Holdings, Inc., Curium Pharma, GE HealthCare Technologies Inc., Cardinal Health, Inc., and Jubilant Pharmova Limited, alongside other participants such as Eckert & Ziegler, Nordion, and NorthStar Medical Radioisotopes. Competitive positioning increasingly depends on reliable isotope supply, manufacturing capacity, regulatory compliance, distribution efficiency, product development, and the ability to maintain consistent availability of Tc-99m-based products. Companies are also focusing on supply-chain resilience because molybdenum-99 availability, reactor capacity, transportation requirements, and radioactive-material regulations can affect the continuity of Technetium-99m supply.
About Transparency Market Research
Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.
Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.
Media Contact:Â
Abhishek Budholiya
Transparency Market Research Inc.
State Tower, 90 State Street, Suite 700,
Albany NY – 12207, United States
Tel: +1-518-618-1030
USA – Canada Toll Free: 866-552-3453